Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial

NCT02835534 is registered in ClinicalTrials.gov with CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. as lead sponsor.

NCT NCT02835534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02835534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial
Lead sponsor
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2016
Completion date
January 31, 2020
Enrollment
818 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute st elevation myocardial infarction